4 IDEAYA/GSK presentations of IDE275 (GSK959) and 4 additional presentations across IDE397/MAT2A, IDE161/PARG, PRMT5, and KAT6/7 programs at AACR 2025 IDE275 (GSK959) has demonstrated a potential best ...
EMBRACE reported 12-month suppression rates of 94% (IV N6LS+CAB LA), 82% (SC), and 88% (oral SOC), with no virologic failures and no new clinically significant AEs after month 6. Presentations focused ...
BioChaperone® is a proprietary platform tailored to solve peptide formulation issues by means of non-covalent molecular complexation. The oral presentation at the PODD (Partnership Opportunities in ...
For presentations scheduled prior to 1:00 PM, please go to the SHED Atrium between 8:00 and 8:30 AM and load your final presentation. For presentations scheduled after 1:00 PM, please go to the SHED ...
Ivan Bergstein, M.D., CEO of Stemline Therapeutics, commented, “We are honored that ASH has selected ELZONRIS data as the subject of three presentations, including an oral presentation of clinical ...
6. Presentation Title: Phase 2 trial of transarterial chemoembolization followed by sintilimab (anti-PD-1), oxaliplatin, and S-1 combined with either trastuzumab (HER-2 positive) or apatinib (HER-2 ...
When you speak, it matters. How you speak makes all the difference. Joy Javits, a public speaking professional from In the Public Eye, is pleased to offer Drexel University graduate students a FREE ...
Oral presentations will be scheduled in one hour time blocks between 8:45 AM and 1:00 PM in the Campus Center and SAU. Presentations will be grouped by theme or topic area. Presenters will be notified ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results